Efficacy of Oral Versus Injectable Iron in Patients With Chronic Kidney Disease: A Two-Year Cross-Sectional Study Conducted at a Rural Teaching Hospital.
chronic kidney disease
hemoglobin
intravenous iron
oral iron
serum ferritin
transferrin saturation
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
05
07
2022
accepted:
31
07
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
6
9
2022
Statut:
epublish
Résumé
Aim Anaemia (particularly iron deficiency) is of important concern in patients with chronic kidney disease (CKD) as it reflects the outcome of the disease. Current recommendations for the use of intravenous iron (IV) therapy in the management of anaemia in such patients are limited. This study highlights the comparison of oral to intravenous iron in patients with chronic kidney disease. Materials and methods This is a prospective case-control study comparing intravenous iron to oral iron in chronic kidney disease patients admitted to the Medicine Department of Acharya Vinoba Bhave Rural Hospital, in central India from October 2018 to October 2020. A total of 150 patients were divided into two groups of 75 each, one receiving oral iron (ferrous sulfate 325 mg tablets) and the other intravenous iron (IV iron sucrose). Results Serum iron, serum ferritin, and transferrin saturation (TS) showed increased levels in the IV iron group than in the oral iron group. In the IV group, a statistically significant increase was found in haemoglobin levels after therapy among all stages of kidney disease (p<0.05) while the same was not reported in the oral iron group. Conclusion IV iron sucrose therapy had been found to be effective, well-tolerated, and more successful than oral iron treatment in chronic kidney disease patients as far as the parameter of iron deficiency anaemia is concerned.
Identifiants
pubmed: 36060352
doi: 10.7759/cureus.27529
pmc: PMC9427239
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e27529Informations de copyright
Copyright © 2022, Agrawal et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nephrol Dial Transplant. 2011 May;26(5):1599-607
pubmed: 20929915
Nephrol Dial Transplant. 2013 Apr;28(4):953-64
pubmed: 23222534
Hematology Am Soc Hematol Educ Program. 2010;2010:338-47
pubmed: 21239816
Nephrol Dial Transplant. 2016 Apr;31(4):646-55
pubmed: 26250435
Nephrol Dial Transplant. 2014 Apr;29(4):833-42
pubmed: 23963731
Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238
pubmed: 11229970
J Am Soc Nephrol. 2015 Jun;26(6):1238-47
pubmed: 25542967
Clin Kidney J. 2017 Dec;10(Suppl 1):i16-i24
pubmed: 29225819
Am J Kidney Dis. 2000 Jul;36(1):88-97
pubmed: 10873877
Nephrol Dial Transplant. 2001 May;16(5):967-74
pubmed: 11328902
Indian J Nephrol. 2015 Jul-Aug;25(4):213-21
pubmed: 26199472
Ann Med Health Sci Res. 2013 Oct;3(4):492-7
pubmed: 24379997
Semin Hematol. 2015 Oct;52(4):261-9
pubmed: 26404438
Nephrol Dial Transplant. 2003 Jan;18(1):141-6
pubmed: 12480972
Nephrol Dial Transplant. 2010 Mar;25(3):920-6
pubmed: 19906658
Hemodial Int. 2010 Jan;14(1):47-54
pubmed: 19888949
Nephron Clin Pract. 2005;100(3):c55-62
pubmed: 15824508
Nephrol Dial Transplant. 2014 Nov;29(11):2075-84
pubmed: 24891437
JNMA J Nepal Med Assoc. 2011 Jul-Sep;51(183):133-6
pubmed: 22922860
Kidney Int. 2015 Oct;88(4):905-14
pubmed: 26083656
Am J Nephrol. 2006;26(5):445-54
pubmed: 17035697
J Assoc Physicians India. 2003 Feb;51:170-4
pubmed: 12725261
J Am Soc Nephrol. 2008 Aug;19(8):1599-605
pubmed: 18525001
Kidney Int. 2005 Dec;68(6):2846-56
pubmed: 16316362
Am J Kidney Dis. 2008 Nov;52(5):897-906
pubmed: 18845368
J Am Coll Cardiol. 2000 Jun;35(7):1737-44
pubmed: 10841219
Clin Kidney J. 2016 Feb;9(1):135-41
pubmed: 26798474